

Increased Susceptibility to Metabolic Syndrome in Adult Offspring of Angiotensin Type 1 Receptor Autoantibody-Positive Rats

Suli Zhang,^{1,2} Xi Zhang,³ Lihong Yang,¹ Zi Yan,¹ Li Yan,¹ Jue Tian,⁴ Xiaoyu Li,¹ Li Song,³ Li Wang,¹ Xiaoli Yang,⁵ Ronghua Zheng,¹ Wayne Bond Lau,⁶ Xinliang Ma,⁶ and Huirong Liu^{1,3,7}

Abstract

Aims: Abnormal fetal and early postnatal growth is closely associated with adult-onset metabolic syndrome (MetS). However, the underlying etiological factors remain complex. The presence of the autoantibody against the angiotensin II type 1 receptor (AT1-Ab), a known risk factor for pre-eclampsia, may create a suboptimal intrauterine fetal environment. The current study investigated whether middle-aged offspring of AT1-Ab-positive mothers were prone to metabolic disorder development. **Results:** The AT1-Abs was detected in placental trophoblastic cells, capillary endothelium, and milk of pregnant rats actively immunized with the second extracellular loop of the AT1 receptor. AT1-Abs in newborn rats induced vasoconstriction, increased intracellular-free Ca^{2+} *in vitro*, and was undetectable 7 weeks later. Immunized group offspring exhibited increased weight variability and insulin resistance at 40 weeks of age under a normal diet, evidenced by elevated fasting serum insulin and homeostasis model assessment score compared with the vehicle control. To further observe metabolic alterations, the offspring were given a high-sugar diet (containing 20% sucrose) 40–48 weeks postnatally. The fasting plasma glucose in immunized group offspring was markedly increased. Concomitantly, these offspring manifested increased visceral adipose tissue, increased fatty liver, increased triglycerides, decreased high-density lipoprotein cholesterol, and decreased adiponectin levels, indicative of MetS. **Innovation:** AT1-Abs could be transferred from mother to offspring *via* the placenta and milk. Moreover, offspring of an AT1-Ab-positive mother were more vulnerable to MetS development in middle age. **Conclusion:** AT1-Ab-positivity of mothers during pregnancy is a previously unrecognized “silent” risk factor for MetS development in their offspring. *Antioxid. Redox Signal.* 17, 733–743.

Introduction

WITH CURRENT LIFESTYLE changes and the global epidemic of obesity, a striking increase in the number of people with metabolic syndrome (MetS) has taken place worldwide. The syndrome is considered to be closely related to a high risk of cardiovascular diseases (CVD) and type 2 diabetes mellitus, which are major causes of morbidity and mortality in the world (21, 22, 31). To our knowledge, complex interactions between genes, an atherogenic diet, a sedentary lifestyle, and environmental factors could lead to MetS. However, growing evidence has highlighted the fetal origin of

Innovation

The current study demonstrated for the first time that the autoantibody against the angiotensin II type 1 receptor (AT1-Abs) (an adverse factor existing in pre-eclamptic patients as well as in a small number of normotensive pregnant women) was transferred from mother rats to their offspring *via* the placenta/milk and caused insulin resistance and increased susceptibility to metabolic syndrome (MetS), a major risk factor for cardiovascular disease. These findings identified that AT1-Abs in mothers is a risk factor that should not be ignored because of the possibility of the development of MetS in their descendents.

¹Department of Physiology, Shanxi Medical University, Taiyuan, Shanxi, People's Republic of China.

²The Key Laboratory of Medical Electrophysiology, Luzhou Medical College, Luzhou, Sichuan, People's Republic of China.

³Department of Pathophysiology, School of Basic Medical Sciences, Capital Medical University, Beijing, People's Republic of China.

⁴Department of Pathophysiology, Ningxia Medical University, Yinchuan, Ningxia, People's Republic of China.

⁵Department of Reproductive Center, Taiyuan Central Hospital, Taiyuan, Shanxi, People's Republic of China.

⁶Department of Emergency Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania.

⁷The Key Laboratory of Remodeling-related Cardiovascular Diseases, Capital Medical University, Ministry of Education, Beijing, People's Republic of China.

the adult disease (FOAD) hypothesis, which proposes that adult-onset MetS and CVD are also closely associated with the intrauterine and initial extrauterine stages of life. Multiple insults, including maternal exposure to harmful factors, inadequate placental perfusion, and/or poor/excess maternal nutrition, may result in intrauterine growth restriction (IUGR), with extenuating consequences on adult health. However, the etiology and pathogenesis of FOAD are complex and not fully understood at present (15, 20, 28).

Recently, evidence about the autoantibody against the angiotensin II type 1 receptor (AT1-Ab), first detected in nearly all women with severe pre-eclampsia and in a small number of normotensive pregnant women, might lead to the fact that IUGR has emerged (12). This autoantibody specifically recognizes the functional epitope of the second extracellular loop of the AT1 receptor (amino-acid residues 165–191, AT1R-EC_{II}), possessing AT1 receptor agonist-like pathological effects (29). Previous studies demonstrated that AT1-Ab might cause impaired placental perfusion *via* varied mechanisms (30), such as enhancing NADPH-reactive oxygen species production (4), minimizing trophoblast invasion (32), and increasing placental cell apoptosis *in vitro* (12). Interestingly, a clinical study reported that the AT1-Ab was also detected in the fetal cord blood of antibody-positive mothers (10). The onslaughts just mentioned may contribute to pathological placental injury, limiting intrauterine fetal growth and maturation. However, there is a lack of more direct evidence demonstrating how the antibody affects offspring development. The potential path by which the maternal AT1-Ab transference to offspring occurs is unclear. The biological properties of the AT1-Ab within offspring require further elucidation. Most importantly, whether the antibodies might exert negative effects on offspring health in later years is completely unknown.

Therefore, the aims of the current study were to (i) determine the route(s) of AT1-Ab transference from mother rats to offspring; (ii) study whether the AT1-Ab present in newborn rats is biologically active; and (iii) investigate whether such offspring have increased susceptibility to MetS on maturation.

Results

Successful establishment of AT1-Ab-positive female rat models by active immunization

Of the 12 actively immunized female rats, 10 generated increased serum AT1-Ab levels 2 weeks after initial immunization, determined by an enzyme-linked immunosorbent assay (ELISA). As seen in Figure 1A, the target antibody level peaked at the 8th week (optical density [OD] value, 2.76 ± 0.09 *vs.* 0.33 ± 0.02 , $p < 0.01$ *vs.* the vehicle group at the same time point), indicating a successful establishment of the active immunization model. The AT1-Ab was not detected in the vehicle group. Additionally, AT1-Abs were of the immunoglobulin G (IgG) isotype (Fig. 1A), not IgM (OD value, 0.07 ± 0.00 *vs.* 0.08 ± 0.00 , $p > 0.05$ *vs.* the vehicle group, Fig. 1B) or IgA (OD value, 0.11 ± 0.01 *vs.* 0.10 ± 0.01 , $p > 0.05$ *vs.* the vehicle group, Fig. 1C). Immunized rats not producing AT1-Abs were not used in this study.

Sodium dodecylsulfonate–polyacrylate gel electrophoresis (SDS-PAGE) showed that two strong bands were seen at 55 and 25 kDa, representing the heavy and light chains of total IgGs from the immunized rats, respectively (Fig. 1D). The IgG subclass of AT1-Abs in immunized rats was determined to be

mostly IgG2b (OD value, 0.35 ± 0.04 *vs.* 0.08 ± 0.01 , $p < 0.01$ *vs.* the vehicle group, Fig. 1E), with a minor percentage belonging to the IgG2a subclass (OD value, 0.10 ± 0.01 *vs.* 0.08 ± 0.01 , $p < 0.05$ *vs.* the vehicle group, Fig. 1E).

AT1-Abs transport capacity and the pathways involved

By 20 days postconception, the sera of intrauterine fetal rats of immunized mothers were AT1-Ab-positive, with a P/N value ([specimen OD–blank control OD]/[negative control OD–blank control OD]) (19) > 2.1 (OD value, 2.32 ± 0.10) according to the ELISA detection. The vehicle group sera were AT1-Ab-negative, with a P/N value < 1.5 (OD value, 0.13 ± 0.01 , $p < 0.01$ *vs.* the immunized group, Fig. 2A). As seen in Figure 2B, strong staining was visualized within the villus placental trophoblast cell layer and fetal vascular endothelium (short arrow) of the immunized group, indicating the AT1-Ab presence. The AT1-Ab distribution was very similar to that of total placental IgGs (long arrow). The staining pattern results suggested general placental IgG crossing in the vehicle group, but no AT1-Abs were identified.

Figure 2C demonstrated that milk obtained from the neonatal gastric contents (7) in the immunized group contained significantly higher AT1-Ab titers than the vehicle group after 1 week of nursing (OD value, 1.34 ± 0.11 *vs.* 0.19 ± 0.03 , $p < 0.01$). To obtain more evidence that mothers' milk is another route *via* which AT1-Abs are passed to newborns, cross-feeding was initiated. Three pairs of mother rats met the inclusion criteria for this experiment phase (one pair was excluded due to refusing breastfeeding). After 7 days, AT1-Abs were manifested in the sera of the female newborn vehicle rats breastfed by the immunized mothers (OD value, 2.60 ± 0.05 *vs.* 0.16 ± 0.03 , $p < 0.01$ *vs.* male newborn vehicle rats, Fig. 2D). In contrast, the AT1-Ab levels in the sera of the immunized female newborn rats fell sharply after they had been fed by the vehicle mother rat milk (OD value, 1.04 ± 0.12 *vs.* 2.62 ± 0.08 , $p < 0.01$ *vs.* male newborn rats in the immunized group). The experiment was repeated with mother rats exchanging male infants, with similar results (Supplementary Fig. S1; Supplementary Data are available online at www.liebertonline.com/ars), confirming the transference of AT1-Abs *via* mothers' milk.


Biological activity of AT1-Abs in the immunized group's newborns

Elevated titers of AT1-Abs were still present in the sera of 22-day-old (normal weaning age) immunized group rats, but not in the vehicle group offspring rats (2.22 ± 0.10 *vs.* 0.13 ± 0.01 , $p < 0.01$, Fig. 3A). Antibody titers gradually declined and were undetectable after the 7th week.

As shown in Figure 3B, $1 \mu\text{M}$ IgG fractions isolated from AT1-Ab-positive newborn rats induced significant vasoconstriction, similar to angiotensin II (AT1 receptor agonist) of the same concentration (contraction values, 0.44 ± 0.05 g and 0.49 ± 0.07 g, respectively). Furthermore, the vasoconstrictive response was markedly blocked (0.05 ± 0.02 g, $p < 0.01$ *vs.* IgG from immunized group offspring) by $10 \mu\text{M}$ losartan (AT1 receptor blocker). The IgG fractions from vehicle newborns demonstrated no vasoconstrictive effects, even at IgG concentrations of $5 \mu\text{M}$.

As summarized in Figure 3C and Supplementary Video S1, within 8 min, a significant increase of intracellular Ca^{2+} level

FIG. 1. Production of auto-antibody against the angiotensin II type 1 receptor (AT1-Abs) titers was generated in female rats immunized with human second extracellular loop of AT1 receptor (AT1R-EC_{II}), and the immunoglobulin (Ig) class/subclass was determined. Female Wistar rats were actively immunized with AT1R-EC_{II}. Sera production of IgG isotype AT1-Ab (A, IgG-AT1-Ab), immunoglobulin M isotype AT1-Ab (B, IgM-AT1-Ab), and immunoglobulin A isotype AT1-Ab (C, IgA-AT1-Ab) were dynamically monitored by enzyme-linked immunosorbent assay (ELISA). Antibody titer is defined by optical density (OD) value. $n=10-12$. $**p<0.01$ versus the vehicle group at the same period. Immu, immunized group female rats; Vehicle, vehicle group female rats. (D) Total sera IgGs of immunized rats were purified, and evaluated by sodium dodecylsulfate-polyacrylate gel electrophoresis. (E) The IgG1, IgG2a, IgG2b, and IgG2c subclasses of AT1-Ab were determined by ELISA. $n=10-12$. $*p<0.05$, $**p<0.01$ versus vehicle. Immu, immunized group IgGs; Vehicle, vehicle group IgGs.



in cultured aortic smooth muscle cells (SMC) was apparent after stimulation with IgG fractions from the immunized group newborn rats ($1 \mu\text{M}$). Maximal change of fluorescence occurred after 1 min ($p<0.01$ vs. vehicle IgGs) and gradually decreased. Cellular preincubation with losartan ($10 \mu\text{M}$) for 20 min caused markedly reduced and delayed Ca^{2+} uptake, while vehicle IgGs ($1 \mu\text{M}$) had no effect on intracellular Ca^{2+} at any time. These *in vitro* experiments suggested that the circulating AT1-Abs in offspring might activate the AT1 receptor in a pathophysiological fashion.

Offspring body weight at age 0 and 3 weeks

Immunized group newborn rats' birth weights tended to be slightly decreased compared with the vehicle group, but not statistically significant ($p=0.06$, 6.21 ± 0.09 g vs. 6.46 ± 0.09 g, Fig. 4A). Unexpectedly, the immunized group offspring body weight values demonstrated much greater variability compared with the vehicle group. Figure 4B and Supplementary Figure S2 revealed the body weights of both groups of 3-week-old offspring.




FIG. 2. AT1-Abs could be transferred to offspring rats *via* the placenta and mother's milk. **(A)** AT1-Ab-positive/negative female rats ($n=3$ /group) were mated with normal male rats. Twenty days after conception, caesarean sections were performed. Intrauterine infant AT1-Ab sera levels were determined by ELISA. $n=12$. ** $p < 0.01$ versus V-fetus. **(B)** Immunohistochemistry located AT1-Abs (short arrow) and total IgGs (long arrow). The presence of cytoplasmic granules indicated antibody positivity. Scale bar=100 μ m. **(C)** Female rats in the two groups ($n=7-9$) were mated with normal male rats and delivered naturally. After 1 week of nursing, the AT1-Ab levels in mother's milk from several newborns' gastric contents were determined by ELISA. $n=12$. ** $p < 0.01$ versus V milk. **(D)** Mother rats in different groups, but delivering on the same day, were selected for the cross-feeding experiment. One week later, the AT1-Abs in the subgroups were determined. ## $p < 0.01$ versus V. † $p < 0.01$ versus I. V (○), vehicle group male newborns; I-V (●), vehicle group female newborns fed by immunized mother rats; I (▲), immunized group male newborns; V-I (△), immunized group female newborn rats fed by vehicle mother. V, vehicle group; I, immunized group. (To see this illustration in color the reader is referred to the web version of this article at www.liebertonline.com/ars).

The presence of insulin resistance in 40-week-old immunized group offspring given a normal diet

The offspring of AT1-Ab-positive/negative pregnant rats were fed and raised in typical fashion until they reached 40 weeks of age. No significant difference was observed between the two groups with regard to fasting plasma glucose (FPG, 5.60 ± 0.23 mM vs. 5.01 ± 0.21 mM, $p > 0.05$, Fig. 5A) or blood pressure (97.8 ± 2.2 mmHg vs. 100.9 ± 2.9 mmHg, $p > 0.05$, Fig. 5B). However, fasting insulin in the offspring of AT1-Ab-positive mothers was greatly increased (23.6 ± 0.9 μ IU/ml vs. 12.9 ± 0.6 μ IU/ml, $p < 0.01$, Fig. 5C), and the homeostasis model assessment for insulin resistance (HOMA-IR) was also elevated (5.60 ± 0.20 vs. 2.30 ± 0.16 , $p < 0.01$, Fig. 5D).

Development of MetS in adult offspring of the immunized group subject to high-sugar diet challenge

Results presented in Figure 5 demonstrated that the offspring of AT1-Ab-positive pregnant rats developed IR under normal living conditions. To determine whether an impaired insulin response in these animals may contribute to the development of MetS when the animals were fed with high-sugar food, additional experiments were performed. A high-sugar diet (20% sucrose) was administered to the

offspring during postnatal weeks 40–48. FPG in the offspring of AT1-Ab-positive pregnant rats moderately increased at 44 weeks (6.14 ± 0.27 mM vs. 5.56 ± 0.11 mM, $p = 0.067$) and markedly increased at 48 weeks (6.28 ± 0.23 mM vs. the vehicle group 5.28 ± 0.18 mM, $p < 0.01$, Fig. 6A). Dyslipidemia accompanied the hyperglycemia observed. Compared with the vehicle group, an increased ratio of visceral fat weight to body weight (VF/BW, $8.1\% \pm 0.4\%$ vs. $6.0\% \pm 0.5\%$, $p < 0.01$, Fig. 6B), elevated triglycerides (TG, 6.69 ± 0.38 mM vs. 2.57 ± 0.31 mM, $p < 0.01$, Fig. 6C), and decreased high-density lipoprotein cholesterol (HDL-C, 0.47 ± 0.03 mM vs. 0.29 ± 0.03 mM, $p < 0.05$, Fig. 6D) were observed in the immunized group offspring, indicative of MetS.

Additionally, hepatic fat accumulation in the rats was determined. In the immunized group offspring, numerous lipid droplets of various sizes were observed in the hepatocyte cytoplasm. In severe cases, hepatocyte nuclei were peripherally displaced, similar to adipocyte morphology. Portal region vascular dilatation, congestion, and significant inflammatory cell infiltration were observed (Fig. 6E). Vehicle offspring manifested grossly normal lobular architecture. Hepatocytes were arranged in a radial distribution surrounding the central vein. However, mild vascular dilatation, congestion, and inflammatory cell infiltration were observed in some portal regions (Fig. 6E).




FIG. 3. AT1-Abs existed in the early neonatal stage, and provided positive effects on vascular function *in vitro*. (A) Attenuation of AT1-Abs in the sera of immunized group offspring. $n=8-12$. ** $p<0.01$ versus V babies. AT1-Abs, angiotensin AT1 receptor antibodies; V, vehicle group; I, immunized group. (B) The direct effects of angiotensin II (Ang II), IgGs isolated from the sera of immunized group offspring (Ab) and vehicle group offspring (Vehi) on isolated rat aortic rings were observed. The blocking effect of losartan (LST) on immunized group IgG-induced vascular effects (LST+Ab) was also recorded. $n=6$. ** $p<0.01$ versus Vehi; ## $p<0.01$ versus Ab+LST. (C) Effects of Ig on intracellular Ca^{2+} variations ($F-F_0$) in cultured aortic smooth muscle cells were dynamically detected by confocal microscopy for 8 min. For each group, the left image displays the basic intracellular Ca^{2+} level, the middle image displays changes in intracellular Ca^{2+} 1 min after treatment, and the right image demonstrates the differential interference contrast microscope images. Scale bar = 30 μ m. * $p<0.05$, ** $p<0.01$ versus Vehi and Ab+LST. F_0 , the fluorescence intensity at baseline; F , the fluorescence value at each recording time. (To see this illustration in color the reader is referred to the web version of this article at www.liebertonline.com/ars).


Recent clinical and experimental studies have demonstrated that plasma levels of adiponectin, an adipokine with strong antidiabetic and cardioprotective properties, is significantly reduced in obesity and diabetes. To determine whether the offspring of AT1-Abs-positive pregnant rats may have altered adiponectin production, serum adiponectin levels were determined. As summarized in Figure 6F, serum adiponectin levels decreased significantly in the immunized

group offspring compared with the vehicle group ($3818 \pm 612 \mu\text{g/L}$ vs. $5837 \pm 678 \mu\text{g/L}$, $p<0.05$, Fig. 6F).

Discussion

In the current study, we emphasize several important observations, the first of which is that AT1-Abs can be transferred from mother rats to offspring *via* the placenta and

FIG. 4. Abnormal body weights of immunized group newborn rats. (A) The mean birth weight of both immunized and vehicle groups. The number is 47 and 42, respectively. $p=0.06$ versus V newborn. (B) The typical body weight distribution of 3-week-old neonates born to the same mother, immunized and vehicle group. V newborn, vehicle group baby rats; I newborn, immunized group baby rats.






FIG. 5. Changes in glucose metabolism and blood pressure were observed in adult rat offspring. Fasting serum insulin (Fins, C) and the homeostasis model assessment for insulin resistance (HOMA-IR, D), but not fasting plasma glucose (FPG, A) and blood pressure (BP, B), increased in 40-week-old immunized group offspring fed a normal diet, compared with the vehicle group offspring. $n=8/\text{group}$. ** $p<0.01$ versus V offspring. V offspring, offspring rats in vehicle group; I offspring, offspring rats in immunized group.




FIG. 6. Glucose and lipid metabolic balance disrupted in adult offspring given high-sugar diet challenge. Fasting plasma glucose (FPG, A), the ratio of visceral fat/body weight (VF/BW, B), serum triglycerides (TG, C), high-density lipoprotein cholesterol (HDL-C, D), and adiponectin concentration (VF) were detected in offspring rats subject to a high-sugar diet during postnatal weeks 40–48. (E) Morphologic hepatic changes of adult offspring from both immunized (right images) and vehicle groups (left images) were determined by classic hematoxylin-eosin staining. Scale bar = 450 μm (× 100), 180 μm (× 250). $n=8/\text{group}$. * $p<0.05$, ** $p<0.01$ versus V offspring at the same period. V offspring, offspring rats in vehicle group; I offspring, offspring rats in immunized group. (To see this illustration in color the reader is referred to the web version of this article at www.liebertonline.com/ars).

milk. Previous studies have demonstrated that IgG passes through the human placental barrier (yolk sac membrane in rats) and the neonatal enterocyte membrane (where milk is absorbed) through specific major histocompatibility complex class I-related Fc receptor (FcRn) binding. Among four rat IgG subclass types (IgG1, IgG2a, IgG2b, and IgG2c), IgG2a and IgG2b exerted greater affinity for FcRn, and crossed both the placental barrier and the neonatal enterocyte membrane more easily (8, 27). Our current study demonstrated that AT1-Abs in the sera of immunized female rats were predominantly IgG2b, with a very minor portion being IgG2a. These data provide credible theoretical support for the transference of AT1-Abs to offspring *via* the placenta and milk.

The rat yolk sac, similar to the human placenta, engages in maternal IgG transport by way of the syncytiotrophoblast and endothelial monolayer of villus, both of which express FcRn (17). Our current results illustrated that the sera of fetal rats born to antibody-positive pregnant rats contained high levels of AT1-Abs before labor onset; the vehicle group fetuses harbored no AT1-Abs. Such observations are identical to a recent clinical report (10) and suggest the ability of AT1-Abs to cross the rat placenta. Thus, since our current study provided only indirect evidence for antibody transfer, we sought specific morphological evidence identifying placental crossing of AT1-Ab. First, the immunogen, AT1R-EC_{II} peptide, was conjugated to horseradish peroxidase (HRP). We located the target antibody in the yolk sac tissue *via* immunohistochemistry. Similar to general IgGs, AT1-Abs are distributed within the syncytiotrophoblast cell layer and vascular endothelium of the rat placenta in the immunized rat group, providing the first direct evidence for AT1-Abs transference *via* the placenta.

Maternal milk ingestion is another basic IgG transport pathway. Milk IgGs are specifically recognized by FcRn and transported across the newborn rat's intestinal epithelium into the circulation. Due to the difficulty associated with collection, we extracted maternal milk from the stomachs of newborn rats (7). ELISA showed AT1-Ab-positivity in the immunized group milk, making it potentially possible for antibodies to be transferred *via* milk ingestion. However, infant rat's stomach milk had a variety of confounding factors, including saliva, gastric juices, blood, and so on; therefore, the gastric contents might not completely represent pure mothers' milk composition. We then designed a cross-feeding experiment to confirm the transfer of AT1-Abs through milk (5). Due to the difficulty involved in distinguishing neonatal rats (the lack of hair and the tendency of mother rats to eat them when marked with ink or dye), we first separated the neonatal rats from both the immunized and vehicle groups by gender in order to facilitate the distinction among different subgroups. The exchange of the same sex newborns between two groups served as an experimental variable, and the un-exchanged offspring served as a control. AT1-Abs were present in the sera of the vehicle group neonatal rats cross-suckled by the immunized group mother rats after 1 week. Conversely, the AT1-Ab levels in the immunized group offspring markedly decreased after cross-feeding by the vehicle mother rats. Altogether, the data just provided fully demonstrated AT1-Ab transferability *via* milk, further demonstrating the transference mechanisms of AT1-Ab from mother to young.

A second important finding of the current study is that AT1-Abs in newborn rats remain biologically active and exert agonist-like effects through AT1 receptor activation. As seen

in patients harboring autoantibodies (26, 33), the exogenous administration of AT1-Ab-positive sera IgGs obtained from baby rats induced significant thoracic aortic ring contractions and enhanced intracellular Ca^{2+} in cultured aortic SMC *in vitro*, similar to angiotensin II. These results suggested that early-life exposure to AT1-Abs (including the intrauterine and early postnatal stage) might be dangerous for offspring rats. Thus, excessive activation of the AT1 receptor might result in multiple pathophysiological effects, such as destroying vascular endothelial cells (35), inducing inflammation (4), promoting the secretion of aldosterone, and inhibiting the metabolic effects of insulin (24).

Third and the most clinically significant finding of the present study is that the AT1-Ab-positive offspring harbors several pathological alterations. First, birth weight is an important indicator reflecting fetal health. Abnormal birth weight shares a close relationship with multiple adult-onset diseases according to epidemiological data (2, 6). A non-statistically significant downward trend was observed in AT1-Ab-positive pregnant rat fetal birth weights ($p=0.06$). Interestingly, there was distinctly greater body weight variability in the immunized group newborns compared with the vehicle group during weaning. Second, on reaching 40 weeks old (equivalent to human middle-aged life), having been fed a normal diet, AT1-Ab-positive pregnant rats' offspring exhibited normal FPG and blood pressure, but elevated serum insulin levels and increased HOMA-IR, indicating IR, while the vehicle group's metabolic parameters remained normal. Moreover, IR is a precursor to MetS, which may be due to genetic changes and/or adverse environmental factors (13, 18). The present study's data suggest that offspring born to AT1-Ab-positive mothers may have increased susceptibility to metabolic derangement by middle age. Finally, the offspring of AT1-Ab-positive pregnant rats were more sensitive to a high-sugar diet challenge. By 48 weeks postnatally, offspring of AT1-Ab-positive mothers demonstrated impaired fasting glucose, impaired glucose tolerance (Supplementary Fig. S3), increased visceral fat deposits, high TG, and low HDL-C, with normotension (data not shown), meeting the criteria for MetS criteria (1). In comparison, rats of the vehicle mothers subjected to the same conditions were of a nearly normal metabolic profile.

Direct/indirect impaired effects of AT1-Abs on the development of the placenta may explain the lower birth weight of rat offspring in the present study (4, 12, 32). AT1-Abs might contribute to uteroplacental ischemia/hypoxia, which is followed by increased fetoplacental vascular resistance and finally resulting in poor nutrient supply to the fetus (23). Then, for survival, the fetus would adapt its physiological development, including downregulating its growth, resetting the endocrine systems and metabolic homeostasis (28). Although beneficial for survival *in utero*, the fetus would be maladaptive and sensitive to metabolic and CVD when exposed to mismatched postnatal environments, such as catch-up growth, an atherogenic diet, and other risk factors.

Recently, both clinical and animal research suggest that the epigenetic modulation of transcription is partially responsible for the links between prenatal and postnatal influences and an increased risk of adult-onset diseases. Nutrient restriction in early life may directly induce epigenetic changes in growth and regulatory-related genes, which will cause permanent structural and functional alterations of important organs,

such as the liver, pancreas, kidney, and the hypothalamic-pituitary-adrenal axis. Additionally, the phenotypic effects of epigenetic modifications during development may not manifest until later in life, especially when responding to environmental challenges (9, 14). Therefore, in our study, we speculated that the large degree of variation in offspring birth weights may be due to interactions between variations in the environment, adaptive epigenetics, and individual behavior. Furthermore, the mechanisms underlying the close association between early-life exposure to AT1-Abs and increased susceptibility to adult-onset MetS may be destroyed tissues and organs *via* various pathways (such as restricting nutrition, activating inflammatory cytokines) and/or epigenetic modulation of key genes. In addition, the oxidative stress and inflammation-related signal pathways (mitogen-activated protein kinase pathway, nuclear factor- κ B signaling pathway, and so on) may play critical roles in the process (3, 4, 11, 25). However, the precise underlying mechanisms responsible are the subject of ongoing study.

In summary, we have demonstrated that AT1-Abs can be transferred from mother rats to their offspring and increase the offspring's risk of developing IR and MetS in middle and late life. These results strongly suggest that the AT1-Ab-positivity of mothers during pregnancy is a previously unrecognized "silent" risk factor for the development of MetS in their offspring. Since MetS has become one of the major public-health challenges worldwide, therapeutic interventions that block the adverse effects of AT1-Abs during pregnancy, or preventive actions (*e.g.*, a low-sugar, low-calorie diet) taken by the descendants of AT1-Ab-positive pregnant women, may be novel strategies in the battle against MetS and its cardiovascular complications.

Study limitations

We used an active immunization rat model in the present study. As a classic method for autoimmune disease research, active immunization with a given autoantigen is easy to operate and widely applied. However, the levels of antibodies produced in the experimental animals are difficult to control, because the process depends on not only the dose of the antigen, but also the individual's immune status. The AT1-Ab levels in the mother rats in our study are a little higher than those in pre-eclamptic patients (36). We will use an alternative rat model that will be passively immunized with AT1-Ab in future studies. Furthermore, with a new model, various potential risk factors for MetS development, such as insulin, leptin, adiponectin, aldosterone, tumor necrosis factor- α , and glucocorticoid, should be dynamically monitored throughout the process. Another phenomenon which needs further exploration is that there is no hypertension in the offspring. It may be due to the complex regulation of blood pressure *in vivo* (such as depressor reflex) or our failure to capture the transient increase in blood pressure.

Materials and Methods

Animals

AT1-Ab-negative female (for establishing an active immunization model) and male (for mating) Wistar rats (8 weeks old) were used. All research procedures complied with the "Guiding Principles in the Use and Care of Animals" pub-

lished by the National Institutes of Health (NIH Publication No. 85-23, Revised 1996) and were approved by the Institutional Animal Care and Use Committee of the Shanxi Medical University. The normal rat diet contained 280 g farina tritici, 125 g wheat bran, 375 g corn flour, 65 g soybean meal, 25 g fish meal, 2.5 g calcium lactate, 1.25 g probiotics, and 10 g salt per kilogram. The high-sugar diet was supplemented with 20% sucrose. The rat food was provided by the Experimental Animal Center of the Shanxi Medical University, China (production license No. SCXK[Jin] 2009-0001).

Immunization protocol

The peptide corresponding to the sequence of human AT1R-EC_{II} was synthesized as previously reported (35). Twenty-four female Wistar rats were randomly assigned to two groups. The immunized group rats were actively immunized with synthetic AT1R-EC_{II} peptide every 2 weeks as per the previous protocol (19). After 8 weeks, immunized female rats were mated with normal male rats (nonimmunized). During pregnancy and nursing periods, the female rats received monthly immunization. Thus, the mother rat models that possessed a relatively stable level of AT1-Ab would be established (35). Caudal vein blood was drawn before each immunization, and serum was collected to monitor antibody generation using the ELISA method as previously reported. The level of AT1-Ab was expressed as OD value, which is also called absorbance (*A*). $A_{\lambda} = \lg(I_0/I)$, where *I* is the transmitted light intensity at a specified wavelength λ and *I*₀ is the incident light intensity. The absorbance is proportional to the concentration of the absorbing species in the sample and usually used to reflect the relative concentration of a sample. Acting as a reference, a control sample is essential. The positivity of the sample to AT1-Ab was also defined as $P/N \geq 2.1$, while the negativity was defined as $P/N \leq 1.5$ (35). The vehicle group rats were treated with a mixture of Freund's complete/incomplete adjuvant (without antigen) and saline in an identical manner.

Preparation of IgG and the subclasses identification

Total IgGs from the sera of immunized female rats containing maximal AT1-Abs were extracted by Mab Trap Kit (Amersham). Extraction purity was assessed by conventional SDS-PAGE. The IgGs from the vehicle group sera were obtained by an identical protocol. The purified IgGs subclasses were identified by ELISA methods. The dilution ratios of biotinylated goat anti-rat IgG1, 2a, 2b, and 2c antibodies (AbD Serotec) were 1:6000, 1:6000, 1:8000, and 1:8000, respectively.

HRP-AT1R-EC_{II} probe preparation

AT1R-EC_{II} antigen peptides were conjugated with HRP utilizing a Glue-B-type-activated HRP conjugation kit (Galaxy Bio). Briefly, the AT1R-EC_{II} antigen peptide was diluted in double-distilled water to a concentration of 1 mg/ml. One hundred microliters of antigen solutions were added to the activated HRP (the HRP/antigen molecular molar ratio was maintained at around 30:1). The reaction body was regulated at pH 9.5 by a starting agent and incubated overnight at 4°C or at 37°C for 2 h. Then, 10 μ l of stop solution was added and mixed for 15 min to cease the reaction. The mixtures were dialyzed for 48 h by dialysis bags with MW10000

interception. The water was changed six times to completely remove free AT1R-EC_{II} peptides. Antigen molecules-HRP conjugates in liquid state were adjusted to pH 7.0 by 1 M phosphate buffer. This HRP-AT1R-EC_{II} probe could specially recognize AT1-Abs, and was stored at -40°C until needed.

Immunohistochemistry

Location of AT1-Abs. Twenty-day pregnant (in labor) rats were intraperitoneally anesthetized with 10% chloral hydrate (3 ml/kg), and caesarean operations commenced. The placentas were removed and fully perfused with phosphate-buffered saline (PBS, pH 7.2) *via* the umbilical vein. The tissues were then fixed in 4% paraformaldehyde solution, and embedded in paraffin. Sections were cut at 8 μm and mounted onto glass slides. After dewaxing and hydrating, 3% H_2O_2 was added, and the samples were incubated for 10 min at room temperature. After three washings with PBS (5 min per time), the slides were subjected to high-pressure antigen retrieval (0.01 M sodium citrate buffer, pH 6.0, 270°C , 10 min), followed by another three PBS washings. The AT1R-EC_{II} peptides conjugated to HRP (diluted in 5% PBS-Milk-Tween(PMT) solution [5% bovine serum albumin or 5% skimmed milk in PBS with 0.1% Tween-20], 1:100) were added and incubated overnight at 4°C . After another PBS washing, the slides were subjected to a diaminobenzidine (DAB) staining reagent.

Distribution of general IgGs. Placental samples were treated with rabbit anti-rat IgG antibody (diluted 1:200 in PMT; Bioss. Inc.) and incubated overnight at 4°C . Then, biotinylated goat anti-rabbit IgG secondary antibody was added and incubated at 37°C for 20 min. The process was repeated with HRP-labeled avidin under the same conditions. A PBS washing was performed following every step, concluding with a DAB staining reagent. The appearance of intracytoplasmic brown granules indicated the target antibody presence.

Milk collection and cross-feeding design

Mother rats' milk was collected from the stomachs of newborns after nursing as per a classically utilized technique (7). The AT1-Ab content of the milk was determined by ELISA *via* the same process as serum antibody detection.

In the cross-feeding experiment protocol, the immunized group and vehicle group mother rats that delivered on the same day were paired. Their newborns were separated by gender. In one pair of mother rats, male newborns were fed by their mother, and female newborns were exchanged for cross-feeding by the opposite group's mother. There were four subgroups: the vehicle group male newborn rats; the immunized group female newborn rats fed by the vehicle mother rats; the immunized group male newborn rats; and the vehicle group female newborn rats fed by the immunized mother rats. After 7 days of feeding, the serum AT1-Ab levels were compared among the subgroups. In another pair of mother rats, the female newborns were fed by their mother, and the male newborns were exchanged for cross-feeding.

Preparation of thoracic aorta rings

To determine whether the AT1-Ab present in offspring sera was biologically active, total AT1-Ab-positive/negative

IgGs in the offspring sera were purified by the previous method. The effects of the IgGs on thoracic aorta and intracellular-free Ca^{2+} in SMC were observed *in vitro*. The vasoconstriction of thoracic aorta rings was performed as previously described (33).

Determination of intracellular-free Ca^{2+}

Male Wistar rats were anesthetized with 10% chloral hydrate (3 ml/kg, intraperitoneal injection). The thoracic aortic SMC were isolated and primarily cultured. Intracellular-free Ca^{2+} concentration in SMC was monitored utilizing Fluo-3/AM, a common fluorescent Ca^{2+} indicator, in the dark (34). The changes in intracellular Ca^{2+} were defined as the difference between the fluorescence intensity at each recording time and the baseline fluorescence value. Ten cells in each group were randomly selected for image analysis.

Metabolism test

After a 12-h overnight fast, the levels of blood glucose, insulin, TG, and HDL-C were analyzed. Plasma glucose levels were determined by an automated glucose oxidase method (One Touch Ultra; LifeScan). Serum insulin was detected by a commercial double-antibody solid-phase radioimmunoassay (Coat-A-Count; DPC). Serum TG and HDL-C were assessed with an autoanalyzer (VetAce). HOMA-IR was calculated as $(\text{FPG} [\text{mM}] \times \text{fasting insulin} [\mu\text{IU}/\text{ml}]) / 22.5$ (16). Both sides of the perirenal and epididymal fat weights were recorded as the visceral fat weight, and VF/BW was calculated. In addition, serum adiponectin was detected by an ELISA kit (R&D). Blood pressure was determined by tail-cuff plethysmography.

Statistical analysis

All data were described as mean \pm standard error of mean. Statistical analysis was performed with the SPSS 15.0 program. The *t*-test was used to compare two independent sample means, and one-way ANOVA was utilized for comparing means of more than two samples. The intracellular Ca^{2+} variations in different groups were compared by repeated-measures ANOVA. All pregnant rats and their offspring were randomly assigned to different experiments. A *p*-value < 0.05 was considered statistically significant.

Acknowledgments

The authors are grateful to Lindsey Devillier for correcting the English spelling and grammar. This study was supported by grants from the Key Laboratory of Medical Electrophysiological Open Foundation of the Sichuan Province, KZ201110025023 from the Science and Technology Plan Project of the Beijing Municipal Education Commission, the NSFC 30900584, the NSFC 81070263, and the Basic Research Project of the Shanxi Province 2008011076-2.

Author Disclosure Statement

No competing financial interests exist.

References

1. Alberti KG, Zimmet P, and Shaw J. Metabolic syndrome—a new world-wide definition. A consensus statement from the International Diabetes Federation. *Diabet Med* 23: 469–480, 2006.

2. Bruce KD and Hanson MA. The developmental origins, mechanisms, and implications of metabolic syndrome. *J Nutr* 140: 648–652, 2010.
3. Dechend R, Homuth V, Wallukat G, Kreuzer J, Park JK, Theuer J, Juepner A, Gulba DC, Mackman N, Haller H, and Luft FC. AT(1) receptor agonistic antibodies from pre-eclamptic patients cause vascular cells to express tissue factor. *Circulation* 101: 2382–2387, 2000.
4. Dechend R, Viedt C, Müller DN, Ugele B, Brandes RP, Wallukat G, Park JK, Janke J, Barta P, Theuer J, Fiebeler A, Homuth V, Dietz R, Haller H, Kreuzer J, and Luft FC. AT1 receptor agonistic antibodies from preeclamptic patients stimulate NADPH oxidase. *Circulation* 107: 1632–1639, 2003.
5. do Vale TG, da Silva AV, Lima DC, de Lima E, Torres LB, Cossa AC, de Oliveira EM, Cabral FR, Cavalheiro EA, Naffah-Mazzacoratti Mda G, and Amado D. Seizures during pregnancy modify the development of hippocampal interneurons of the offspring. *Epilepsy Behav* 19: 20–25, 2010.
6. Ellis KJ. Body composition in infancy: impact on health later in life. *Nestle Nutr Workshop Ser Pediatr Program* 65: 213–220, 2010.
7. Fusaro AE, Maciel M, Victor JR, Oliveira CR, Duarte AJ, and Sato MN. Influence of maternal murine immunization with dermatophagoides pteronyssinus extract on the type I hypersensitivity response in offspring. *Int Arch Allergy Immunol* 127: 208–216, 2002.
8. Ghetie V and Ward ES. Transcytosis and catabolism of antibody. *Immunol Res* 25: 97–113, 2002.
9. Guilloteau P, Zabielski R, Hammon HM, and Metges CC. Adverse effects of nutritional programming during prenatal and early postnatal life, some aspects of regulation and potential prevention and treatments. *J Physiol Pharmacol* 3: 17–35, 2009.
10. Herse F, Dechend R, Harsem NK, Wallukat G, Janke J, Qadri F, Hering L, Muller DN, Luft FC, and Staff AC. Dysregulation of the circulating and tissue-based renin-angiotensin system in preeclampsia. *Hypertension* 49: 604–611, 2007.
11. Hitomi H, Kaifu K, Fujita Y, Sofue T, Nakano D, Moriwaki K, Hara T, Kiyomoto H, Kohno M, Kobori H, and Nishiyama A. Angiotensin II shifts insulin signaling into vascular remodeling from glucose metabolism in vascular smooth muscle cells. *Am J Hypertens* 24: 1149–1155, 2011.
12. Irani RA, Zhang Y, Blackwell SC, Zhou CC, Ramin SM, Kellems RE, and Xia Y. The detrimental role of angiotensin receptor agonistic autoantibodies in intrauterine growth restriction seen in preeclampsia. *J Exp Med* 12: 2809–2822, 2009.
13. Jeppesen J, Hansen TW, Rasmussen S, Ibsen H, Torp-Pedersen C, and Madsbad S. Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease: a population-based study. *J Am Coll Cardiol* 49: 2112–2119, 2007.
14. Joss-Moore LA and Lane RH. The developmental origins of adult disease. *Curr Opin Pediatr* 21: 230–234, 2009.
15. Kanaka-Gantenbein C. Fetal origins of adult diabetes. *Ann N Y Acad Sci* 1205: 99–105, 2010.
16. Karcz-Socha I, Zwirska-Korczala K, Zembala M, Borgiel-Marek H, and Karcz K. Ghrelin PYY 3-36 serum changes in left ventricular hypertrophic, insulin-resistant, hypertensive obese patients. *Obes Facts* 4: 386–392, 2011.
17. Kim J, Mohanty S, Ganesan LP, Hua K, Jarjoura D, Hayton WL, Robinson JM, and Anderson CL. FcRn in the yolk sac endoderm of mouse is required for IgG transport to fetus1. *J Immunol* 182: 2583–2589, 2009.
18. Lee HK. Mitochondrial dysfunction and insulin resistance: the contribution of dioxin-like substances. *Diabetes Metab J* 35: 207–215, 2011.
19. Liu HR, Zhao RR, Zhi JM, Wu BW, and Fu ML. Screening of serum autoantibodies to cardiac beta1-adrenoceptors and M2-muscarinic acetylcholine receptors in 408 healthy subjects of varying ages. *Autoimmunity* 29: 43–51, 1999.
20. McMillen IC and Robinson JS. Developmental origins of the metabolic syndrome: prediction, plasticity, and programming. *Physiol Rev* 85: 571–633, 2005.
21. Misra A, Singhal N, and Khurana L. Obesity, the metabolic syndrome, and type 2 diabetes in developing countries: role of dietary fats and oils. *J Am Coll Nutr* 29: 289S–301S, 2010.
22. Scott R, Donoghoe M, Watts GF, O'Brien R, Pardy C, Taskinen MR, Davis TM, Colman PG, Manning P, Fulcher G, and Keech AC. Impact of metabolic syndrome and its components on cardiovascular disease event rates in 4900 patients with type 2 diabetes assigned to placebo in the FIELD randomised trial. *Cardiovasc Diabetol* 10: 102, 2011.
23. Sebire NJ and Talbert D. 'Cor placental': placental intervillous/intravillous blood flow mismatch is the pathophysiological mechanism in severe intrauterine growth restriction due to uteroplacental disease. *Med Hypotheses* 57: 354–357, 2001.
24. Stiefel P, Vallejo-Vaz AJ, García Morillo S, and Villar J. Role of the Renin-Angiotensin system and aldosterone on cardiometabolic syndrome. *Int J Hypertens* 2011: 685238, 2011.
25. Strawn WB. Pathophysiological and clinical implications of AT(1) and AT(2) angiotensin II receptors in metabolic disorders: hypercholesterolaemia and diabetes. *Drugs* 62: 31–41, 2002.
26. Thway TM, Shlykov SG, Day MC, Sanborn BM, Gilstrap LC 3rd, Xia Y, and Kellems RE. Antibodies from preeclamptic patients stimulate increased intracellular Ca²⁺ mobilization through angiotensin receptor activation. *Circulation* 110: 1612–1619, 2004.
27. Van de Perre P. Transfer of antibody via mother's milk. *Vaccine* 21: 3374–3376, 2003.
28. Vickers MH. Developmental programming of the metabolic syndrome—critical windows for intervention. *World J Diabetes* 2: 137–148, 2011.
29. Wallukat G, Homuth V, Fischer T, Horstkamp B, Jüpner A, Baur E, Nissen E, Vetter K, Dudenhausen JW, Haller H, and Luft FC. Patients with preeclampsia develop agonistic antibodies against the angiotensin AT1 receptor. *J Clin Invest* 103: 945–952, 1999.
30. Walther T, Wallukat G, Jank A, Bartel S, Schultheiss HP, Faber R, and Stepan H. Angiotensin II type 1 receptor agonistic antibodies reflect fundamental alterations in the uteroplacental vasculature. *Hypertension* 46: 1275–1279, 2005.
31. Wilson PWF, D'Agostino RB, Parise H, Sullivan L, and Meigs JB. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. *Circulation* 112: 3066–3072, 2005.
32. Xia Y, Wen H, Bobst S, Day MC, and Kellems RE. Maternal autoantibodies from preeclamptic patients activate angiotensin receptors on human trophoblast cells. *J Soc Gynecol Investig* 10: 82–93, 2003.
33. Yang X, Wang F, Chang H, Zhang S, Yang L, Wang X, Cheng X, Zhang M, Ma XL, and Liu H. Autoantibody against AT1 receptor from preeclamptic patients induces vasoconstriction through angiotensin receptor activation. *J Hypertens* 26: 1629–1635, 2008.
34. Zhang HG, Cheng YQ, Liu Y, Zhou JZ, Jia Y, Wang XQ, and Li XH. Gzq-protein carboxyl terminus imitation polypeptide

GCIP-27 attenuates proliferation of vascular smooth muscle cells and vascular remodeling in spontaneously hypertensive rats. *Biol Pharm Bull* 34: 1527–1532, 2011.

35. Zhang SL, Du YH, Wang J, Yang LH, Yang XL, Zheng RH, Wu Y, Wang K, Zhang MS, and Liu HR. Endothelial dysfunction induced by antibodies against angiotensin AT1 receptor in immunized rats. *Acta Pharmacol Sin* 31: 1381–1388, 2010.
36. Zhou CC, Zhang Y, Irani RA, Zhang H, Mi T, Popek EJ, Hicks MJ, Ramin SM, Kellems RE, and Xia Y. Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice. *Nat Med* 14: 855–862, 2008.

Address correspondence to:

Prof. Huirong Liu
Department of Pathophysiology
School of Basic Medical Sciences
Capital Medical University
10 Xitoutiao, You An Men
Beijing 100069
People's Republic of China

E-mail: liuhr2000@126.com

Date of first submission to ARS Central, October 26, 2011; date of final revised submission, January 29, 2012; date of acceptance, January 29, 2012.

Abbreviations Used

AT1-Ab = autoantibody against the angiotensin II type 1 receptor
AT1R-EC_{II} = second extracellular loop of the AT1 receptor
AUC = area under the glucose curve
CVD = cardiovascular diseases
DAB = diaminobenzidine
ELISA = enzyme-linked immunosorbent assay
FOAD = fetal origin of adult disease
FPG = fasting plasma glucose
HDL-C = high-density lipoprotein cholesterol
HOMA-IR = homeostasis model assessment for insulin resistance
HRP = horseradish peroxidase
IR = insulin resistance
IUGR = intrauterine growth restriction
MetS = metabolic syndrome
OD = optical density
OGTT = oral glucose tolerance test
PBS = phosphate-buffered saline
PMT = PBS-Milk-Tween
SDS-PAGE = sodium dodecylsulfonate–polyacrylate gel electrophoresis
SMC = smooth muscle cells
VF/BW = ratio of visceral fat weight to body weight